- Discussions advance on global co-development and commercialization strategies for dPCR-based liquid biopsy and MRD diagnostics
- Finalizing U.S. market entry strategy for LDT, including FDA approval
[by Jin, Yu Jeong] 해외 바카라 사이트, a precision medicine-centered molecular diagnostics company, announced on January 9 that it will participate in the 44th JP Morgan Healthcare Conference (JPM 2026), to be held in San Francisco, USA, with the objective of strengthening its global market presence.
At the conference, Gencurix plans to conduct a series of meetings with the so-called ‘Big 3’ leaders in the global molecular diagnostics market: Roche, QIAGEN, and Bio-Rad Laboratories.
Through these 해외 바카라 사이트, the company intends to review the status of its ongoing business collaborations with these global partners and to discuss key agenda priorities, including the expansion of its digital PCR (dPCR)-based cancer molecular diagnostics portfolio and the further acceleration of its global market expansion strategy.
The collaboration will center on dPCR-based cancer biomarker diagnostics, with a particular focus on next-generation solutions for cancer detection and treatment monitoring, including minimal residual disease (MRD) assessment and liquid biopsy-based testing.
해외 바카라 사이트 further stated that it intends to leverage its participation in JPM 2026 as an opportunity to flesh out its U.S. market entry strategy. In particular, the company plans to engage in discussion on key strategic issues such as potential collaboration models with local laboratory-developed test (LDT) service providers, mid- to long-term market entry pathways considering U.S. Food and Drug Administration (FDA) approval and reimbursement listing, and the delineation of roles and cooperative structure with global partners.
"This conference will serve as an opportunity to review the progress of major commercialization projects currently underway in collaboration with leading global companies and, on that basis, to explore further expansion of our product portfolio and market reach. Through global partnerships, we aim to accelerate our entry into key international markets, including the United States, while diversifying and reinforcing our revenue structure," said Park Jeong-do, Vice President of Gencurix.